Roclanda 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IB/0023/G 
This was an application for a group of variations. 
09/02/2024 
B.II.c.1.z - Change in the specification parameters 
and/or limits of an excipient - Other variation 
B.II.d.2.z - Change in test procedure for the finished 
product - Other variation 
amended 
on 
Annex II and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.b.z - Change in manufacture of the Finished 
Product - Other variation 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0024 
B.II.b.4.a - Change in the batch size (including batch 
16/01/2024 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
PSUSA/10905
Periodic Safety Update EU Single assessment - 
11/01/2024 
n/a 
PRAC Recommendation - maintenance 
/202306 
latanoprost / netarsudil 
N/0022 
Minor change in labelling or package leaflet not 
12/12/2023 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10905
Periodic Safety Update EU Single assessment - 
06/07/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
latanoprost / netarsudil 
IB/0018 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
05/07/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0019 
B.II.d.1.h - Change in the specification parameters 
14/06/2023 
n/a 
and/or limits of the finished product - Update of the 
dossier to comply with the provisions of an updated 
general monograph of the Ph. Eur. for the finished 
product 
II/0011 
B.I.a.1.b - Change in the manufacturer of AS or of a 
01/06/2023 
n/a 
starting material/reagent/intermediate for AS - 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction of a manufacturer of the AS supported 
by an ASMF 
IG/1627 
A.5.b - Administrative change - Change in the name 
29/05/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0017 
B.II.z - Quality change - Finished product - Other 
23/05/2023 
n/a 
variation 
IB/0015 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
28/03/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0013 
B.I.a.1.z - Change in the manufacturer of AS or of a 
20/01/2023 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
PSUSA/10905
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202206 
latanoprost / netarsudil 
N/0012 
Minor change in labelling or package leaflet not 
12/12/2022 
24/03/2023 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0010 
B.III.2.a.1 - Change of specification(s) of a former 
17/11/2022 
n/a 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008/G 
This was an application for a group of variations. 
15/09/2022 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10905
Periodic Safety Update EU Single assessment - 
07/07/2022 
n/a 
PRAC Recommendation - maintenance 
/202112 
latanoprost / netarsudil 
IB/0007/G 
This was an application for a group of variations. 
27/06/2022 
n/a 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.4.c - Change in shape or dimensions of the 
container or closure (immediate packaging) - Sterile 
medicinal products 
B.II.e.2.d - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition or replacement of a 
specification parameter as a result of a safety or 
quality issue 
II/0002 
C.I.4, Update of sections 4.8 and 5.1 of the SmPC in 
02/06/2022 
24/03/2023 
SmPC and PL 
For more information, please refer to the Summary of 
Product Characteristics. 
order to update efficacy and safety information 
based on final results from study PG324-CS303; this 
is a prospective, double-masked, randomised, 
multicentre, active-controlled, parallel-group, 6-
month study assessing the safety and ocular 
hypotensive efficacy of Roclanda compared to 
bimatoprost + timolol in subjects with elevated 
intraocular pressure that was insufficiently controlled 
and/or deemed to be in need of combination IOP-
lowering therapy. The Package Leaflet is updated 
accordingly. 
Page 5/7 
 
 
 
 
 
 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0006/G 
This was an application for a group of variations. 
29/03/2022 
24/03/2023 
SmPC, 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IAIN/0004/G 
This was an application for a group of variations. 
02/03/2022 
24/03/2023 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0003 
Transfer of Marketing Authorisation 
11/01/2022 
04/02/2022 
SmPC, 
Labelling and 
PL 
PSUSA/10905
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
latanoprost / netarsudil 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 7/7 
 
 
 
 
 
 
 
